Negative inotropic effect of rapamycin on isolated human cardiomyocytes

Journal of International Medical Research

Volumn 36, Issue 4, 2008, Pages 810-814

  Möllmann, Helge ^a   Nef, H M ^a   Kahlert, P ^b   Kostin, S ^c   Mollmann S ^a   Weber, M ^a   Troidl, C ^a   Hamm, C W ^a   Holubarsch, C J F ^d   Elsasser A ^a  

^a KERCKHOFF HEART CENTER   (Germany)

^b West German Heart Center   (Germany)

^c MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^d MEDIAN Kliniken GmbH   (Germany)

Author keywords

Contractility; Isolated cardiomyocytes; Rapamycin; Sirolimus

Indexed keywords

CALCIUM ION; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 12.6; ISOPRENALINE; RAPAMYCIN; RYANODINE RECEPTOR; UNCLASSIFIED DRUG; CALCIUM; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CALCIUM HOMEOSTASIS; CELL STRUCTURE; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DIASTOLE; ELECTROSTIMULATION; EXTRACELLULAR CALCIUM; HEART ATRIUM APPENDAGE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HUMAN; HUMAN CELL; INOTROPISM; SARCOPLASMIC RETICULUM; SMOOTH MUSCLE CONTRACTION; CELL CULTURE; CELL SHAPE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; HEART CONTRACTION; METABOLISM; PHYSIOLOGY;

CALCIUM; CELL SHAPE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; SIROLIMUS;

EID: 52049125026     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600424     Document Type: Article

References (13)

1. Roiron C, Sanchez P, Bouzamondo A, et al: Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart 2006; 92: 641-649.
2. Sata M, Fukuda D, Tanaka K, et al: The role of circulating precursors in vascular repair and lesion formation. J Cell Mol Med 2005; 9: 557-568.
3. Camenzind E, Steg PG, Wijns W: Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007; 115: 1440-1455; discussion 1455.
4. Meier P, Zbinden R, Togni M, et al: Coronary collateral function long after drug-eluting stent implantation. J Am Coll Cardiol 2007; 49: 15-20.
5. Kahan BD: Sirolimus-based immuno-suppression: present state of the art. J Nephrol 2004; 17(suppl 8): S32-S39.
6. Mollmann H, Schmidt-Schweda S, Nef H, et al: Contractile effects of angiotensin and endothelin in failing end non-failing human hearts. Int J Cardiol 2007; 114: 34-40.
7. Kostin S, Schaper J: Tissue-specific patterns of Gap junctions in adult rat atrial and ventricular cardiomyocytes in vivo and in vitro. Circ Res 2001; 88: 933-939.
8. Li SY, Fang CX, Aberle NS 2nd, et al: Inhibition of PI-3 kinase/ Akt/mTOR, but not calcineurin signaling, reverses insulin-like growth factor I-induced protection against glucose toxicity in cardiomyocyte contractile function. J Endocrinol 2005; 186: 491-503.
9. Brillantes AB, Ondrias K, Scott A, et al: Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell 1994; 77: 513-523.
10. Timerman AP, Onoue H, Xin HB, et al: Selective binding of FKBP12.6 by the cardiac ryanodine receptor. J Biol Chem 1996; 271: 20385-20391.
11. 2+ leak from the sarcoplasmic reticulum and increases contractility. Circ Res 2001; 88: 188-194.
12. Wessely R, Schomig A, Kastrati A: Sirolimus and paclitaxel on polymer-based drug-eluting stents: similar but different. J Am Coll Cardiol 2006; 47: 708-714.
13. MacDonald A, Scarola J, Burke JT, et al: Clinical pharmocokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000; 22(suppl B): B101-B121.